Autoimmune Encephalitis Clinical Trial
— Generate-BoostOfficial title:
A Multicenter Randomized, Controlled, Double-blinded Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis
Autoimmune Encephalitis is a disorder of the central nervous system caused by bodily substances, called antibodies. Antibodies normally help the body to prevent infections. However, in this disorder, the antibodies turn against the body itself and especially against cells in the brain and disturb the normal brain function. They are therefore called autoantibodies. There is no specific therapy for patients with autoimmune encephalitis so far. At the moment, the symptoms are treated with approved medications such as cortisone and immunotherapies also used in oncology. These therapies are unspecified and aim to reduce the number of autoantibodies and to contain the autoimmune process. In this trial we aim to test a new therapy option: in this therapy the body cells producing autoantibodies will be specifically targeted by a substance called bortezomib. The trial addresses patients with severe autoimmune encephalitis. The aim of the trial is to evaluate the efficacy and safety of bortezomib in patients with severe autoimmune encephalitis.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | April 30, 2026 |
Est. primary completion date | November 30, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Clinically diagnosed severe autoimmune encephalitis (defined as mRS = 3) with autoantibodies to neuronal surface proteins in cerebrospinal fluid and / or serum - Pretreatment with rituximab - Age =18 years - signed informed consent - Women of childbearing potential (up to 2 years after menopause): negative pregnancy test Exclusion Criteria: - pregnancy/breast-feeding - acute infiltrative pulmonary and pericardial disease - malignant tumor under current chemotherapy - Simultaneous participation in another intervention study - Previous participation in this study - Known hypersensitivity to an ingredient of the investigational product - Continued therapy with glucocorticoids / rituximab during the study duration (last dose must be administered before the first dose of the investigational product) |
Country | Name | City | State |
---|---|---|---|
Germany | Charité - Universitätsmedizin Berlin, Klinik für Neurologie mit Experimenteller Neurologie | Berlin | |
Germany | Ruhr-Universität Bochum, St. Josef Hospital, Klinik für Neurologie | Bochum | |
Germany | University Hospital Düsseldorf, Clinic for Neurology | Düsseldorf | |
Germany | Universitätsklinikum Erlangen, Neurologische Klinik | Erlangen | |
Germany | Universitätsklinikum Essen (AöR), Klinik für Neurologie | Essen | |
Germany | University Hospital Frankfurt (Main), Clinic for Neurology | Frankfurt | |
Germany | Universitätsmedizin Göttingen Georg-August-Universität, Klinik für Neurologie | Göttingen | |
Germany | Universitätsmedizin Greifswald, Klinik und Poliklinik für Neurologie | Greifswald | |
Germany | Medizinische Hochschule Hannover | Hannover | Niedersachen |
Germany | Universitätsklinikum Jena, Sektion Translationale Neuroimmunologie, Klinik für Neurologie | Jena | |
Germany | Klinik für Neurologie UKSH, Campus Kiel | Kiel | |
Germany | Universitätsklinikum Leipzig, Klinik und Poliklinik für Neurologie | Leipzig | |
Germany | Universitätsmedizin Mainz, Klinik und Poliklinik für Neurologie | Mainz | |
Germany | Ludwig-Maximilians-Universität München, Klinikum Großhadern | München | Bayern |
Germany | Universitätsklinikum Münster Klinik für Neurologie | Münster | |
Germany | Universitätsklinikum Ulm, Klinik für Neurologie Neurologische Ambulanz | Ulm | |
Germany | Universitätsklinikum Würzburg | Würzburg | Bayern |
Lead Sponsor | Collaborator |
---|---|
Jena University Hospital |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | modified Rankin-Score (mRS) | modified Rankin-Score from 0 = no symptoms to 6 = death | 17 weeks after first administration of the study drug | |
Secondary | modified Rankin-Score (mRS) | modified Rankin-Score from 0 = no symptoms to 6 = death | 3, 6, 9 and 13 weeks after first administration of the study drug; GCS Score also 17 weeks after first administration of the study drug | |
Secondary | Length of in-hospital stay / length of ICU stay | Number of days in hospital or on ICU for each patient from first administration of the study drug until 17 weeks after first administration of the study drug | until 17 weeks after first administration of the study drug | |
Secondary | Immune response | Antibody titer (in serum and liquor) and cellular immune response (FACS analysis of liquor) | at study start and 17 weeks after first administration of the study drug | |
Secondary | neurocognitive function assessed by Montreal Cognitive Assessment | total score of the Montreal Cognitive Assessment (MoCA) (0 to max. 30 points = best possible result) | at study start and 17 weeks after first administration of the study medication | |
Secondary | neurocognitive function assessed by Mini-Mental Status Test | total score of the Mini-Mental Status Test (MMST) (0 to max 30 points = best possible result) | at study start and 17 weeks after first administration of the study medication | |
Secondary | neurocognitive function assessed by Rey Auditory Verbal Learning Test | total score of the Rey Auditory Verbal Learning Test (RAVLT) (memory performance assessed by 3 word lists which are read to the patient and should be recalled and repeated by the patient; different proceeding for the 3 word lists) | at study start and 17 weeks after first administration of the study medication | |
Secondary | neurocognitive function assessed by Neuropsychiatric Inventory Questionnaire | total score of the Neuropsychiatric Inventory Questionnaire (NPI) (0 = best score to max 36 (patient) or 60 (caregiver) | at study start and 17 weeks after first administration of the study medication | |
Secondary | safety of Bortezomib regarding polyneuropathy, increase of liver enzymes and secondary infections | number of polyneuropathy cases, number of increased liver enzymes, number of secondary infections | until 17 weeks after first administration of the study drug | |
Secondary | safety of Bortezomib regarding polyneuropathy | number of polyneuropathy cases | until 17 weeks after first administration of the study drug | |
Secondary | safety of Bortezomib regarding increase of liver enzymes | number of increased liver enzyme values | until 17 weeks after first administration of the study drug | |
Secondary | Secondary infections due to Bortezomib | number of secondary infections | until 17 weeks after first administration of the study drug | |
Secondary | Hematotoxicity events due to Bortezomib | number of hematotoxicity events | until 17 weeks after first administration of the study drug | |
Secondary | Gastrointestinal toxicity due to Bortezomib | number of gastrointestinal toxicity events | until 17 weeks after first administration of the study drug | |
Secondary | total Glasgow Coma Scale (GCS) | GCS from 3 to 15 points (sum of 3 subscores eye response (1 to 4 points), motor response (1 to 6 points), verbal response (1 to 5 points); highest score = best score; 1= worst score) | 3, 6, 9, 13 and 17 weeks after first administration of the study drug | |
Secondary | Destruction marker UCH-L1 (Ubiquitin carboxy-terminal hydrolase L1) in serum and liquor | Analysis of destruction marker UCH-L1 in serum and liquor | at baseline visit and 17 weeks after first administration of the study drug | |
Secondary | Destruction marker Neurofilament light chain (in serum and liquor) | Analysis of destruction marker Neurofilament light chain in serum and liquor | at baseline visit and 17 weeks after first administration of the study drug | |
Secondary | Destruction markers GFAP (glial fibrillary acidic protein) in serum and liquor | Analysis of destruction marker GFAP in serum and liquor | at baseline visit and 17 weeks after first administration of the study drug | |
Secondary | Destruction marker TAU proteins in serum and liquor | Analysis of destruction marker TAU in serum and liquor | at baseline visit and 17 weeks after first administration of the study drug |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04561557 -
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
|
Early Phase 1 | |
Completed |
NCT05645185 -
Characterisation of Clinical Phenotypes and Outcomes of Ma2 Patient
|
||
Completed |
NCT04708626 -
Epidemiology of Autoimmune Encephalitides and Paraneoplastic Neurological Syndromes in Sweden
|
||
Not yet recruiting |
NCT04106596 -
HLA Analysis in Autoimmune Encephalitis and Related Disorders
|
||
Not yet recruiting |
NCT05711563 -
Predicting and Monitoring Outcomes in Autoimmune Encephalitis
|
||
Completed |
NCT04175522 -
Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis:
|
Phase 2 | |
Recruiting |
NCT03194815 -
IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2
|
Phase 2 | |
Recruiting |
NCT06079294 -
Impact of Confirmed Autoimmune Encephalitis on Brain Glucose Metabolism
|
N/A | |
Not yet recruiting |
NCT03957616 -
Incidence of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis
|
||
Completed |
NCT02905136 -
Mechanisms of Auto-immune Encephalitis
|
||
Recruiting |
NCT05280600 -
Developing Advanced Neuroimaging for Clinical Evaluation of Autoimmune Encephalitis
|
||
Recruiting |
NCT06173076 -
A Prospective Study to Evaluate Clinical Outcomes in Anti-LGI1 Encephalitis
|
||
Recruiting |
NCT06033846 -
Efficacy and Safety of Adjunctive Minocycline in the Treatment of Autoimmune Encephalitis
|
Phase 2 | |
Recruiting |
NCT04372615 -
The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
|
Phase 2 | |
Recruiting |
NCT05177939 -
Phase III Clinical Study of NPB-01 in Patients With Autoimmune Encephalitis
|
Phase 3 | |
Active, not recruiting |
NCT06432803 -
Metabolic Imaging for Diagnosis and Prognostication of Autoimmune encephalitiS
|
||
Recruiting |
NCT06019975 -
FDG-PET in the Diagnosis of Autoimmune Encephalitis
|
||
Completed |
NCT05783947 -
Diagnostic Performance of a Commercial Assay for the Detection of Neuronal Antibodies
|
||
Not yet recruiting |
NCT06456736 -
Clinical Features and Prognostic Markers in Adult Patients With AE Requiring ICU Treatment
|
||
Completed |
NCT05825690 -
BRIEF TITLE * (in English and Sufficiently Descriptive) Role of MRI in Anti-LGI1 Encephalitis
|